HEALTH

Disney will end health insurance for employees' spouses with access to other coverage in 2027, citing rising costs, despite record profits. The change affects over 200,000 employees.

Recent studies reveal GLP-1 weight loss drugs like Ozempic and Wegovy offer unexpected benefits, including reduced alcohol cravings and arthritis relief, but also pose risks like muscle loss and gastrointestinal issues.

Moderna's shares surged 90% after a successful Phase 3 trial of its mRNA cancer vaccine for melanoma, developed with Merck, showing significant benefits over existing treatments.

Ticketmaster's new identity verification process aims to prevent bots from buying tickets, but raises privacy concerns among users due to the collection of biometric and personal data.

Amylyx Pharmaceuticals' shares soared 48% after announcing positive Phase 3 trial results for avexitide, a drug targeting post-bariatric hypoglycemia, marking a significant milestone for the biotech company.

Mesoblast shares surged 8.82% on the ASX after a volatile week, recovering losses from a securities filing that unsettled investors. The company's revenue growth and clinical progress remain key focus areas.

Alamar Biosciences reported an 82% revenue growth in Q2 2026, issued its first full-year revenue guidance, and launched new products, boosting its stock by 17.58% since its IPO in April.

AbCellera Biologics' stock surged over 30% after its menopause drug, ABCL635, showed significant efficacy in a Phase 2 trial, reducing hot flash frequency and severity, with no serious adverse events.

Iovance Biotherapeutics' shares rose 34% after reporting record second-quarter revenue and receiving FDA Fast Track Designation for its cancer therapy, Amtagvi, signalling strong growth and investor confidence.

4DMedical Ltd's shares surged 9.77% as its diagnostic software gains traction in U.S. hospitals, marking a 1,250% increase over 12 months, driven by commercial milestones and regulatory developments.

Neuren Pharmaceuticals' shares rose 17.52% after reporting record sales for DAYBUE, its Rett syndrome treatment, and announcing progress in European market expansion, boosting investor confidence.

Krystal Biotech's Q2 results show strong revenue growth and profitability, but investor concerns over growth pace and international expansion led to a stock decline. The company remains focused on expanding its gene therapy pipeline.

PYC Therapeutics' stock rose 7.06% amid ongoing advancements in RNA-based treatments for rare genetic diseases, supported by a strong financial position and promising clinical trial results.

4DMedical's stock has surged 1,250% over the past year, driven by strategic acquisitions, new contracts, and expanding market presence, despite ongoing volatility and valuation concerns.

The U.S. Department of Veterans Affairs is conducting a clinical trial to test if semaglutide, a diabetes medication, can help veterans with alcohol addiction by affecting the brain's reward system.

Abbott Laboratories' shares rose 2.37% after reporting strong Q2 results and raising its 2026 earnings guidance, driven by growth in diagnostics, devices, and strategic acquisitions.

Huron Consulting Group's stock surged 32.11% after reporting Q2 earnings that exceeded expectations and raising its full-year guidance, driven by growth in AI-related services and recent acquisitions.

AbbVie shares reached a 52-week high as investors anticipate the company's second-quarter earnings report, focusing on its immunology portfolio and recent strategic acquisitions.

Johnson & Johnson's shares soared to a record high after agreeing to a $5.5 billion settlement to resolve 76,000 U.S. lawsuits alleging its talc products caused ovarian cancer, removing a major legal overhang.

Kiniksa Pharmaceuticals' shares rose over 21% following strong Q2 results, surpassing expectations and raising its full-year sales outlook for ARCALYST, the only FDA-approved therapy for recurrent pericarditis.

Microsoft introduces MAI-Cyber-1-Flash, an AI model designed to identify cybersecurity vulnerabilities, outperforming rivals at lower costs. Integrated into Project Perception, it marks a significant shift in Microsoft's security strategy.

Thermo Fisher Scientific's shares surged after reporting strong Q2 results, surpassing expectations and raising full-year guidance, indicating a recovery in the life sciences sector.

Taco Bell introduces $1 menu deals to attract customers back after a cyclospora outbreak linked to its lettuce. The company swiftly removed the affected produce and continues to investigate the source.

NovoCure's shares jumped 25% following record quarterly revenue and an improved financial outlook, marking a recovery from earlier setbacks, including a failed clinical trial and insider share sales.

The FDA corrected a false positive test for Cyclospora in Taylor Farms de Mexico's lettuce, but the recall remains as the investigation into the outbreak affecting over 1,600 people continues.

A cyclosporiasis outbreak linked to Taco Bell's lettuce has sickened thousands across 34 states. The CDC advises against consuming the lettuce, while Taco Bell and Taylor Farms take corrective actions.

Trevi Therapeutics' stock rose 13.10% following positive data presentation at a European conference, highlighting Haduvio's potential in treating chronic cough, boosting investor confidence and analyst ratings.

4DMedical shares dropped 15.57% this week, continuing a downward trend as investors reassess the company's valuation. Despite recent commercial successes, market sentiment remains cautious amid broader volatility.

A potential cyclospora outbreak linked to Taylor Farms' lettuce has affected Taco Bell locations, with nearly 7,000 cases reported nationwide. Investigations are ongoing to confirm the source.